课题基金 / 基金详情

项目摘要

项目成果

JOSHUA BECKER的其他基金

相似基金

相关文献

中文摘要
翻译
这个子项目是众多研究子项目之一
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The evaluation of nephrotoxicity has classically been performed by serum creatinine levels obtained 48 to 72 hours after administration of contrast media (CM) - the clinical lag from the renal insult to an altered serum creatinine measure. A 0.5 mg% or a 25% increase of serum creatinine is the standard definition of CIN. No criteria has been established when renal function is assessed by measured glomerular filtration rate (GFR). Little is known of GFR alterations in time shortly after injection. The common simulated GFR evaluation, creatinine clearance, is dependent upon formulas such as Cockcroft and Gault and MDRD (serum creatinine and modifiers). This estimation has a questionable clinical value, since it is dependent upon serum creatinine assays that are known to lag by 48 to 72 hours. Iodinated contrast media is a pure glomerular filtrate (filtered by the glomerulus and is neither excreted nor reabsorbed by the tubules). In small doses (<50 ml) the iodinated CM has no documented impact upon renal function (nephrotoxicity is usually considered to be dose dependent). Utilizing the RENALYZER PRX90 instrument to quantify plasma levels of non isotopic iodine (i.e., concentration of the administered iodine containing radio-opaque CM), GFR can be determined from a single plasma sample. Reliability of the RENALYZER single sample technique has compared favorably with the usual radionuclide 51Cr-EDTA. The goal of this investigation is to measure "real" GFR in patients with normal renal function (serum creatinine <1.4 mg/ml) who will have gadolinium administered for a clinically indicated MRI. Adult patients (>18 years) in need of gadolinium CM-enhanced MRI study will be recruited. The patients will be consented for the MRI study with gadolinium CM enhancement. Prior to the MRI imaging study, GFR determination will be performed utilizing a 30 ml (300 mg/ml) iodine radio-opaque contrast agent, and blood will be drawn. The patients will have their MRI study with the injection of gadolinium CM as per imaging protocol, and blood will be drawn. GFR will be analyzed by RENALYZER GFR determination, which is based upon the plasma attenuation of the iodine in the CM. After three hours (allowing for an equilibrium of extra vascular/intravascular shift), initial investigation with a multi plot graph demonstrated GFR determinations consistent with the x axis (time) and results in a straight line graph. This multiple plot assay subsequently was modified to a singe sample 3 hours after iodinated CM injection. The plasma samples will be analyzed in the RENALYZER in batches. If the GFR determination remains unchanged from the baseline study over the 3 hours, there is a confirmation of no effect of the gadolinium CM upon renal function. However, if there is a decrease in GFR (>25%), this will represent contrast-induced nephrotoxicity. This percentage change was chosen to comply with the accepted 25% increase in serum creatinine for the diagnosis of nephrotoxicity of radio-opaque contrast media. Initial experimentation has shown that gadolinium does not interfere with the Renalyzer assay of iodine, thus justifying the use of an iodinated contrast agent to establish the patient's GFR.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
USING GFR TO MEASURE THE EFFECT OF RADIO-OPAQUE CONTRAST MEDIA ON RENAL FUNCTIO
USING GFR TO MEASURE THE EFFECT OF RADIO-OPAQUE CONTRAST MEDIA ON RENAL FUNCTIO
USING GFR TO MEASURE THE EFFECT OF RADIO-OPAQUE CONTRAST MEDIA ON RENAL FUNCTIO
USING GFR TO MEASURE THE EFFECT OF RADIO-OPAQUE CONTRAST MEDIA ON RENAL FUNCTIO
海外基金